Skip to main content
Caplight Logo









Crossbow Therapeutics

Crossbow Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.crossbowtx.com/

Last Round

Series B

Mar 18, 2026

Est. Valuation

$112.55M

Total Funding Raised

$157M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Crossbow Therapeutics is a biotechnology company developing next-generation T-cell receptor (TCR)-mimetic antibody therapies to treat a broad range of cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

T-cell receptor therapyTCR therapyimmunotherapyoncologyT-cell engagerTCR-mimeticcancer immunotherapysolid tumor treatmentbiotechnologydrug discoveryprecision medicinehematologic malignanciesbiologicsnext-gen cancer drugs

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Crossbow Therapeutics Comparables

Compare Crossbow Therapeutics with similar companies based on industry and business-model similarity.

Crossbow Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Enara Bio
81%
BlueSphere Bio
79%
TScan Therapeutics
78%

Crossbow Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 18, 2026
Series AJul 11, 2023

Key People

Founding team and executive leadership

Briggs Morrison

Chief Executive Officer

Executive Team

Crossbow Therapeutics Investors

Notable investors and investment history

Crossbow Therapeutics investors
InvestorRounds
Libbs VenturesSeries B
LifeLink VenturesSeries B
Sixty Degree CapitalSeries B
Taiho VenturesSeries B
MPM BioImpactSeries B, Series A, Seed
Arkin Bio CapitalSeries B
BVF Partners L.P.Series A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 18, 2026

    $77M round completed.

  • Mar 18, 2026

    Developing novel T-cell engager therapies targeting cancer cells.

Crossbow Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Crossbow Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Crossbow Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range43
Year Founded2021
Last FundingMar 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?